CT and MR Imaging Diagnosis and Staging of Hepatocellular Carcinoma: Part I. Development, Growth, and Spread: Key Pathologic and Imaging Aspects

Overview

Journal Radiology

Specialty Radiology

Date 2014 Aug 26

PMID 25153274

Citations 175

Authors

Jin-Young Choi

Jeong-Min Lee

Claude B Sirlin

Affiliations

Soon will be listed here.

Abstract

Computed tomography (CT) and magnetic resonance (MR) imaging play critical roles in the diagnosis and staging of hepatocellular carcinoma (HCC). The first article of this two-part review discusses key concepts of HCC development, growth, and spread, emphasizing those features with imaging correlates and hence most relevant to radiologists; state-of-the-art CT and MR imaging technique with extracellular and hepatobiliary contrast agents; and the imaging appearance of precursor nodules that eventually may transform into overt HCC.

Citing Articles

Oligometastatic Hepatocellular Carcinoma to the Perirectal Pelvis, a Rare Site of Distant Spread.

Lupu G, Barritt 4th A, Iuga A, Moon A, Sanoff H, Yanagihara T ACG Case Rep J. 2025; 12(2):e01615.

PMID: 39925792 PMC: 11805561. DOI: 10.14309/crj.0000000000001615.

Intracellular enhancement technique for gadoxetic acid-enhanced hepatobiliary-phase magnetic resonance imaging: evaluation of hepatic function.

Fonseca D, Nakamura Y, Higaki T, Maeda S, Nishihara T, Bito Y Abdom Radiol (NY). 2025; .

PMID: 39888382 DOI: 10.1007/s00261-025-04817-y.

Non-medicinal oral contrast in upper abdominal MRI for MR-guided radiotherapy: A scoping review.

Beasley M, Henry A, Bestall J, Cosgrove V, Murray L, Burnett C Radiography (Lond). 2025; 31(2):102868.

PMID: 39863498 PMC: 11904122. DOI: 10.1016/j.radi.2025.01.003.

Super delayed phase imaging in gadoxetic acid-enhanced MRI: investigating factors contributing to improved liver contrast.

Kobayashi T, Kozaka K, Matsubara T, Yokka A, Igarashi S, Kitao A Eur Radiol. 2024; .

PMID: 39613959 DOI: 10.1007/s00330-024-11227-z.

RMCNet: A Liver Cancer Segmentation Network Based on 3D Multi-Scale Convolution, Attention, and Residual Path.

Zhang Z, Gao J, Li S, Wang H Bioengineering (Basel). 2024; 11(11).

PMID: 39593733 PMC: 11591158. DOI: 10.3390/bioengineering11111073.

References

Swan S, Lambrecht L, Townsend R, Davies B, McCloud S, Parker J . Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol. 1999; 34(7):443-8. DOI: 10.1097/00004424-199907000-00001. View

Llovet J, Fuster J, Bruix J . The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004; 10(2 Suppl 1):S115-20. DOI: 10.1002/lt.20034. View

Beasley R, Hwang L, Lin C, Chien C . Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981; 2(8256):1129-33. DOI: 10.1016/s0140-6736(81)90585-7. View

Omata M, Lesmana L, Tateishi R, Chen P, Lin S, Yoshida H . Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010; 4(2):439-74. PMC: 2900561. DOI: 10.1007/s12072-010-9165-7. View

Tamada T, Ito K, Yoshida K, Kanki A, Higaki A, Tanimoto D . Comparison of three different injection methods for arterial phase of Gd-EOB-DTPA enhanced MR imaging of the liver. Eur J Radiol. 2011; 80(3):e284-8. DOI: 10.1016/j.ejrad.2010.12.082. View

Park Y, Kim M . Hepatocarcinogenesis: imaging-pathologic correlation. Abdom Imaging. 2011; 36(3):232-43. DOI: 10.1007/s00261-011-9688-y. View

Park M, Kim Y, Lee M, Lee J . Validation of diagnostic criteria using gadoxetic acid-enhanced and diffusion-weighted MR imaging for small hepatocellular carcinoma (<= 2.0 cm) in patients with hepatitis-induced liver cirrhosis. Acta Radiol. 2012; 54(2):127-36. DOI: 10.1258/ar.2012.120262. View

McGlynn K, London W . The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011; 15(2):223-43, vii-x. PMC: 4141529. DOI: 10.1016/j.cld.2011.03.006. View

Manfredi R, Maresca G, BARON R, De Franco A, De Gaetano A, Cotroneo A . Gadobenate dimeglumine (BOPTA) enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging. 1998; 8(4):862-7. DOI: 10.1002/jmri.1880080416. View

10.

Takeshita K, Nagashima I, Frui S, Takada K, Yamauchi T, Harasawa A . Effect of superparamagnetic iron oxide-enhanced MRI of the liver with hepatocellular carcinoma and hyperplastic nodule. J Comput Assist Tomogr. 2002; 26(3):451-5. DOI: 10.1097/00004728-200205000-00024. View

11.

Ishigami K, Yoshimitsu K, Nishihara Y, Irie H, Asayama Y, Tajima T . Hepatocellular carcinoma with a pseudocapsule on gadolinium-enhanced MR images: correlation with histopathologic findings. Radiology. 2008; 250(2):435-43. DOI: 10.1148/radiol.2501071702. View

12.

Aravalli R, Cressman E, Steer C . Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol. 2012; 87(2):227-47. DOI: 10.1007/s00204-012-0931-2. View

13.

Iguchi T, Aishima S, Sanefuji K, Fujita N, Sugimachi K, Gion T . Both fibrous capsule formation and extracapsular penetration are powerful predictors of poor survival in human hepatocellular carcinoma: a histological assessment of 365 patients in Japan. Ann Surg Oncol. 2009; 16(9):2539-46. DOI: 10.1245/s10434-009-0453-1. View

14.

Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M . Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology. 2002; 225(1):143-9. DOI: 10.1148/radiol.2251011298. View

15.

Golfieri R, Grazioli L, Orlando E, Dormi A, Lucidi V, Corcioni B . Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. J Magn Reson Imaging. 2012; 36(3):648-57. DOI: 10.1002/jmri.23685. View

16.

STEVENS W, Gulino S, Batts K, Stephens D, Johnson C . Mosaic pattern of hepatocellular carcinoma: histologic basis for a characteristic CT appearance. J Comput Assist Tomogr. 1996; 20(3):337-42. DOI: 10.1097/00004728-199605000-00001. View

17.

Takayasu K, Furukawa H, Wakao F, Muramatsu Y, Abe H, Terauchi T . CT diagnosis of early hepatocellular carcinoma: sensitivity, findings, and CT-pathologic correlation. AJR Am J Roentgenol. 1995; 164(4):885-90. DOI: 10.2214/ajr.164.4.7726041. View

18.

Xu P, Yan F, Wang J, Shan Y, Ji Y, Chen C . Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr. 2010; 34(4):506-12. DOI: 10.1097/RCT.0b013e3181da3671. View

19.

Davies B, Kirchin M, Bensel K, Lorusso V, Davies A, Parker J . Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function. Invest Radiol. 2002; 37(5):299-308. DOI: 10.1097/00004424-200205000-00008. View

20.

Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G . Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. World J Gastroenterol. 2007; 13(45):6022-6. PMC: 4250884. DOI: 10.3748/wjg.v13.45.6022. View